Founded with a mission to advance therapeutic antibody discovery, OmniAb partners with the pharmaceutical industry to provide access to diverse antibody repertoires and high-throughput screening technologies. Their core vision is to enable the discovery of next-generation therapeutics, leveraging their proprietary Biological Intelligence (BI) platform. OmniAb offers a comprehensive suite of clinically proven antibody discovery technologies, positioning itself as a key player in the pharmaceutical sector focused on innovative therapeutic solutions.
Notable affiliates and investors include Ligand Pharmaceuticals, which has been instrumental in supporting OmniAb's growth and technological advancements. Key achievements of OmniAb include the successful development and deployment of their advanced antibody discovery platform, which has significantly impacted the pharmaceutical industry by accelerating the development of new therapeutics. OmniAb's contributions have been pivotal in pushing the forefront of therapeutic antibody discovery, making substantial impacts on healthcare and treatment options globally.
